Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | GRM5 | P41594 | 6/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712408 | 0.83 | SMO (0.42) | GRM5POLBP2RX7 | |
| SCHEMBL30254699 | 0.82 | UCHL1 (0.39) | GRM5GRM1USP30POLB | |
| SCHEMBL30427091 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL30426870 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL30426810 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL31105081 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL31104864 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL31105132 | 0.78 | SMARCA2 (0.39) | GPR119GRM5GRM1 | |
| SCHEMBL16271998 | 0.78 | GPR119 (0.47) | GPR119GRM5GRM1 | |
| SCHEMBL20111756 | 0.77 | HTR2A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014192868-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | GPR119 702/4885GRM5 202/4885GRM1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.